CU23970B1 - DIVISIBLE GALENIC FORM THAT ALLOWS A MODIFIED RELEASE OF THE ACTIVE PRINCIPLE - Google Patents
DIVISIBLE GALENIC FORM THAT ALLOWS A MODIFIED RELEASE OF THE ACTIVE PRINCIPLEInfo
- Publication number
- CU23970B1 CU23970B1 CU2008000179A CU20080179A CU23970B1 CU 23970 B1 CU23970 B1 CU 23970B1 CU 2008000179 A CU2008000179 A CU 2008000179A CU 20080179 A CU20080179 A CU 20080179A CU 23970 B1 CU23970 B1 CU 23970B1
- Authority
- CU
- Cuba
- Prior art keywords
- divisible
- modified release
- allows
- active principle
- galenic form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Inorganic Chemistry (AREA)
Abstract
Una fórmula galénica divisible de liberación modificada de principio activo, donde la forma galénica no subdividida y una fracción de dicha forma obtenida por subdivisión tienen un perfil de disolución idéntico. Medicamentos.A divisible galenic formula of modified release of active ingredient, where the non-subdivided galenic form and a fraction of said form obtained by subdivision have an identical dissolution profile. Medicines.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0801561A FR2928836B1 (en) | 2008-03-21 | 2008-03-21 | SECURE GALENIC FORM FOR MODIFIED RELEASE OF THE ACTIVE INGREDIENT |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20080179A7 CU20080179A7 (en) | 2011-04-26 |
CU23970B1 true CU23970B1 (en) | 2013-12-27 |
Family
ID=39796790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2008000179A CU23970B1 (en) | 2008-03-21 | 2008-09-23 | DIVISIBLE GALENIC FORM THAT ALLOWS A MODIFIED RELEASE OF THE ACTIVE PRINCIPLE |
Country Status (37)
Country | Link |
---|---|
US (3) | US20090238870A1 (en) |
EP (2) | EP3025706A1 (en) |
JP (2) | JP5231906B2 (en) |
KR (3) | KR20090101048A (en) |
CN (1) | CN101347414B (en) |
AP (1) | AP2729A (en) |
AR (1) | AR067993A1 (en) |
AU (1) | AU2008207680B8 (en) |
BR (1) | BRPI0803631A2 (en) |
CA (1) | CA2629670C (en) |
CL (1) | CL2008002486A1 (en) |
CO (1) | CO6020017A1 (en) |
CR (2) | CR10317A (en) |
CU (1) | CU23970B1 (en) |
EA (1) | EA200801862A1 (en) |
EC (1) | ECSP088727A (en) |
FR (1) | FR2928836B1 (en) |
GT (1) | GT200800163A (en) |
HK (1) | HK1127280A1 (en) |
HN (1) | HN2008001466A (en) |
IL (1) | IL193611A0 (en) |
JO (1) | JO3052B1 (en) |
MA (1) | MA31218B1 (en) |
ME (1) | ME01031B (en) |
MX (1) | MX2008011579A (en) |
MY (1) | MY150660A (en) |
NI (1) | NI200800256A (en) |
NZ (1) | NZ570715A (en) |
PE (1) | PE20090991A1 (en) |
SA (1) | SA08290555B1 (en) |
SG (1) | SG155819A1 (en) |
SV (1) | SV2008003023A (en) |
TW (1) | TWI396561B (en) |
UA (1) | UA86731C2 (en) |
UY (1) | UY31307A1 (en) |
WO (1) | WO2009125087A1 (en) |
ZA (1) | ZA200807354B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2389666T3 (en) | 2005-09-09 | 2012-10-30 | Angelini Labopharm, Llc | Trazodone composition for once-daily administration |
US20070160960A1 (en) * | 2005-10-21 | 2007-07-12 | Laser Shot, Inc. | System and method for calculating a projectile impact coordinates |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
DE102010015123A1 (en) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TR201103946A1 (en) | 2011-04-22 | 2012-11-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Glyclazide formulations for controlled release. |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
ITFI20130184A1 (en) * | 2013-08-01 | 2015-02-02 | Valpharma Internat S P A | PHARMACEUTICAL FORMULATION OF GLYCLAZIDE WITH MODIFIED RELEASE, ADMINISTRABLE BY ORAL ROUTE, AND ITS PRODUCTION METHOD. |
CN106892856A (en) * | 2017-02-06 | 2017-06-27 | 山东科源制药股份有限公司 | A kind of preparation method of gliclazide crude product recrystallization |
AU2021237693A1 (en) | 2020-03-16 | 2022-09-08 | Grünenthal GmbH | Scored tablet |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH648754A5 (en) * | 1979-08-16 | 1985-04-15 | Ciba Geigy Ag | Pharmaceutical slow release tablet |
US4353887A (en) * | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
US4851230A (en) * | 1983-04-07 | 1989-07-25 | Bristol-Myers Company | Capsule shaped tablets |
GB8724763D0 (en) * | 1987-10-22 | 1987-11-25 | Aps Research Ltd | Sustained-release formulations |
US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
JPH069375A (en) * | 1992-04-10 | 1994-01-18 | Takeda Chem Ind Ltd | Dividable connected tablet |
DE4229085C2 (en) * | 1992-09-01 | 1996-07-11 | Boehringer Mannheim Gmbh | Elongated, divisible tablet |
US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
CA2312990C (en) * | 1997-12-08 | 2008-04-29 | Bristol-Myers Squibb Company | Novel salts of metformin and method |
EA003101B1 (en) * | 1998-03-19 | 2002-12-26 | Бристол-Майерз Сквибб Компани | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
JP2006052230A (en) * | 1998-04-03 | 2006-02-23 | Kyowa Hakko Kogyo Co Ltd | Dividable tablet and press-through pack |
EP0947188B1 (en) * | 1998-04-03 | 2008-03-05 | Kyowa Hakko Kogyo Co., Ltd. | Dividable tablet and press-through pack |
AP1243A (en) * | 1999-02-01 | 2004-02-02 | Servier Lab | Core tablet for controlled release of gliclazide after oral administration. |
CA2371940C (en) * | 1999-03-31 | 2008-07-15 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
US6878749B2 (en) * | 1999-09-17 | 2005-04-12 | Novartis Ag | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
DE10117208A1 (en) * | 2001-04-06 | 2002-10-10 | Wolff Walsrode Ag | Process for the preparation of low-viscosity, aqueous cellulose ether solutions |
CN1294908C (en) * | 2003-06-08 | 2007-01-17 | 安徽省医药科技实业公司 | Oral gliclazide sustained release formulation |
JP2007534704A (en) * | 2004-04-29 | 2007-11-29 | 美時化学製薬股▲ふん▼有限公司 | Oral sustained release tablet composition and method for producing the same |
US7622137B2 (en) * | 2004-05-21 | 2009-11-24 | Accu-Break Technologies, Inc. | Dosage forms contained within a capsule or sachet |
WO2006061697A1 (en) * | 2004-12-06 | 2006-06-15 | Themis Laboratories Private Limited | Sulfonylurea compositions and a process for its preparation |
DE102005014141B4 (en) * | 2005-03-23 | 2006-12-21 | Hennig Arzneimittel Gmbh & Co. Kg | Tablet-shaped delayed-release preparation against dizziness |
EP1868587A2 (en) * | 2005-04-08 | 2007-12-26 | Abbott Laboratories | Pharmaceutical formulations comprising fenofibric acid and/or its salts |
JP5046501B2 (en) * | 2005-08-18 | 2012-10-10 | 帝人ファーマ株式会社 | Tablets that hold multiple drugs separately |
CA2619744C (en) * | 2005-08-18 | 2014-09-02 | Teijin Pharma Limited | Formulation having accurate dose-dividing function |
ES2389666T3 (en) * | 2005-09-09 | 2012-10-30 | Angelini Labopharm, Llc | Trazodone composition for once-daily administration |
JOP20180109A1 (en) * | 2005-09-29 | 2019-01-30 | Novartis Ag | New Formulation |
CN102813635A (en) * | 2006-08-10 | 2012-12-12 | 武田药品工业株式会社 | Pharmaceutical composition |
WO2008062470A2 (en) * | 2006-10-19 | 2008-05-29 | Torrent Pharmaceuticals Limited | Stabilized controlled release dosage form of gliclazide |
JP2008208078A (en) * | 2007-02-27 | 2008-09-11 | Takada Seiyaku Kk | Tablet to be scored |
-
2008
- 2008-03-21 FR FR0801561A patent/FR2928836B1/en active Active
- 2008-04-24 CA CA2629670A patent/CA2629670C/en not_active Expired - Fee Related
- 2008-08-18 EP EP15191226.8A patent/EP3025706A1/en not_active Withdrawn
- 2008-08-18 EP EP08290778A patent/EP2103302A1/en not_active Withdrawn
- 2008-08-20 UA UAA200810556A patent/UA86731C2/en unknown
- 2008-08-21 MY MYPI20083200 patent/MY150660A/en unknown
- 2008-08-21 IL IL193611A patent/IL193611A0/en active IP Right Grant
- 2008-08-21 AR ARP080103637A patent/AR067993A1/en not_active Application Discontinuation
- 2008-08-21 SG SG200806219-2A patent/SG155819A1/en unknown
- 2008-08-21 GT GT200800163A patent/GT200800163A/en unknown
- 2008-08-22 UY UY31307A patent/UY31307A1/en not_active Application Discontinuation
- 2008-08-22 PE PE2008001421A patent/PE20090991A1/en active IP Right Grant
- 2008-08-22 CL CL2008002486A patent/CL2008002486A1/en unknown
- 2008-08-22 US US12/229,418 patent/US20090238870A1/en not_active Abandoned
- 2008-08-22 NZ NZ570715A patent/NZ570715A/en unknown
- 2008-09-02 AU AU2008207680A patent/AU2008207680B8/en active Active
- 2008-09-02 TW TW097133651A patent/TWI396561B/en active
- 2008-09-03 SA SA08290555A patent/SA08290555B1/en unknown
- 2008-09-04 CN CN2008102137696A patent/CN101347414B/en active Active
- 2008-09-08 JP JP2008229452A patent/JP5231906B2/en active Active
- 2008-09-09 EC EC2008008727A patent/ECSP088727A/en unknown
- 2008-09-10 MX MX2008011579A patent/MX2008011579A/en active IP Right Grant
- 2008-09-10 SV SV2008003023A patent/SV2008003023A/en unknown
- 2008-09-11 CO CO08095780A patent/CO6020017A1/en not_active Application Discontinuation
- 2008-09-11 JO JOP/2008/0408A patent/JO3052B1/en active
- 2008-09-15 AP AP2008004614A patent/AP2729A/en active
- 2008-09-19 HN HN2008001466A patent/HN2008001466A/en unknown
- 2008-09-19 EA EA200801862A patent/EA200801862A1/en unknown
- 2008-09-22 KR KR1020080092747A patent/KR20090101048A/en not_active Application Discontinuation
- 2008-09-23 CU CU2008000179A patent/CU23970B1/en active IP Right Grant
- 2008-09-24 CR CR10317A patent/CR10317A/en unknown
- 2008-09-25 NI NI200800256A patent/NI200800256A/en unknown
- 2008-09-25 BR BRPI0803631-4A patent/BRPI0803631A2/en not_active Application Discontinuation
- 2008-10-01 ZA ZA200807354A patent/ZA200807354B/en unknown
- 2008-10-13 MA MA31286A patent/MA31218B1/en unknown
-
2009
- 2009-03-20 WO PCT/FR2009/000295 patent/WO2009125087A1/en active Application Filing
- 2009-03-20 ME MEP-2010-154A patent/ME01031B/en unknown
- 2009-05-11 HK HK09104299.1A patent/HK1127280A1/en unknown
-
2010
- 2010-05-12 JP JP2010109928A patent/JP2010209103A/en active Pending
-
2011
- 2011-09-19 KR KR1020110094146A patent/KR101693189B1/en active IP Right Grant
-
2013
- 2013-06-12 US US13/916,029 patent/US20130295176A1/en not_active Abandoned
-
2014
- 2014-03-12 US US14/206,063 patent/US20140221449A1/en not_active Abandoned
- 2014-07-10 CR CR20140334A patent/CR20140334A/en unknown
-
2015
- 2015-01-12 KR KR20150004248A patent/KR20150035829A/en not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU23970B1 (en) | DIVISIBLE GALENIC FORM THAT ALLOWS A MODIFIED RELEASE OF THE ACTIVE PRINCIPLE | |
CL2014003306A1 (en) | Oral pharmaceutical preparation comprising a bruton tyrosine kinase inhibitor and crystalline form thereof. | |
CL2015000893A1 (en) | Formulation of a solid rapid disintegration pharmaceutical form comprising functionalized calcium carbonate, an active ingredient and at least one disintegrant; and method for its manufacture. | |
CY1119798T1 (en) | FORM IV IV Hydrochloride Ibabradine | |
IT1400982B1 (en) | TRANS-EPITHELIAL OSMOTIC COLLIRIUM FOR THE CARE OF THE KERATOCONO. | |
EA201201263A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING DAGIGATRAN ETEXYLATE | |
IT1404931B1 (en) | OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES. | |
CO6491060A2 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES | |
EA201201202A1 (en) | ORAL PHARMACEUTICAL COMPOSITION CONTAINING DABIGATRANE EXTILE | |
BRPI1014583A2 (en) | heterocyclic sulfonamides, pharmaceutical compositions and uses thereof. | |
CR20120316A (en) | PROCESSES FOR THE MANUFACTURE OF A PHARMACEUTICALLY ACTIVE AGENT | |
BR112012028788A2 (en) | manufacture of granules without assets | |
BR112016007414A2 (en) | method of producing a monolayer tablet, and monolayer tablet | |
UY34786A (en) | PROCEDURE FOR THE MANUFACTURE OF A PHARMACEUTICAL FORM INCLUDING NIFEDIPINO AND CANDESARTAN CILEXETILO | |
BR112012024428A2 (en) | fast dissolving pharmaceutical composition | |
CL2009000904A1 (en) | Compounds derived from cyclohexyl sulfonamides having antagonist activity at the npy y5 receptor, pharmaceutical composition and pharmaceutical formulation comprising them. | |
CO6592109A2 (en) | New crystalline form of a cyclopropylbenzamide derivative | |
CL2013001684A1 (en) | Pharmaceutical composition for oral administration comprising alisporivir, a lipophilic component, a surfactant and a hydrophilic component. | |
BRPI0921225A2 (en) | medicine box and its use. | |
BRPI0920878A2 (en) | ksp161 inhibitor to increase apoptosis, its administration and its use. | |
CY1118277T1 (en) | STABLE PHARMACEUTICAL FORM PEXIGANANIS | |
UY34189A (en) | FUNGICIDE BLENDS THAT INCLUDE ISOXAZOL AND OTHER ACTIVE INGREDIENT. | |
BR112014032501A2 (en) | compound and pharmaceutical composition. | |
DK2268287T3 (en) | DOSAGE SYSTEMS OF ANTITUMUM AGENT, INCLUDING DEOXYCYTIDE INGREDIENT | |
AR094627A1 (en) | CRYSTAL FORMS OF DIHYDROPIRIMIDINE DERIVATIVES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant of patent |